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Background
MGN1703 is a synthetic DNA-based immunomodulator
acting as TLR-9 agonist which has shown preclinical
activity in metastatic colorectal carcinoma (mCRC) as
well as a good safety profile in patients with metastatic
solid tumours in a Phase 1 trial. The IMPACT trial was
conducted to assess clinical efficacy, safety, and immuno-
logical effects of MGN1703 as maintenance therapy twice
weekly s.c. vs. placebo.
Methods
IMPACT was an international randomised (2:1) double-
blind placebo-controlled phase 2 trial in patients with
mCRC who achieved disease control (CR, PR, SD) after
4.5 to 6 months of 1st-line induction chemotherapy with
FOLFOX/XELOX or FOLFIRI +/- bevacizumab. Due to
slow recruitment the trial was prematurely closed in May
2012 after randomisation of 59 out of 129 planned patients
(43 received MGN1703, 16 placebo).
Results
There was evidence of a superior effect of MGN1703
compared with placebo. The hazard ratio (HR) for the
primary endpoint PFS on maintenance treatment group
was 0.55, (p=0.040) on local assessment and 0.56
(p=0.070) by independent radiological review. Notably, at
time of study closure 4 patients receiving MGN1703
were still free of progression and continued treatment in
compassionate use protocols.
Exploratory uni- and multivariate Cox regression ana-
lyses showed a possibly predictive effect of baseline CEA
level and tumour size change during first-line induction
therapy. HR was 0.07 (p<0.0001) for patients with nor-
mal CEA level and 0.39 (p=0.005) for patients with an
objective response to induction chemotherapy.
A predefined analysis was performed on immunological
cell populations at baseline and during the study. This
allowed to confirm activation of innate immune system
effector cells in patients receiving MGN1703. Cox regres-
sion and receiver operating characteristic (ROC) analyses
identified the presence at baseline of activated NKT-cells
(CD3+, CD56+, CD69+) as potentially predictive of benefit
from MGN1703 treatment. The HR was 0.27 (p=0.007)
using a cut-off value for activated NKT-cells of 3.08%.
Conclusions
After induction chemotherapy for mCRC, maintenance
with MGN1703 is associated with improved PFS com-
pared to placebo and low toxicity.
We found preliminary evidence that pretreatment
CEA plasma levels, tumour response and activated NKT
cells counts may allow identifying patients benefiting
most from MGN1703 maintenance therapy. A confirma-
tory clinical study in patients with mCRC is planned to
start in 2014.
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